Mechanisms of Resistance to EGFR-targeted Therapy

Posted On 2020-06-04 03:15:30

Lung cancer is the leading cause of cancer mortality worldwide. Recent progress has improved outcomes for many lung cancer patients. In particular, activating genetic alterations in the oncogenic driver genes such as the epidermal growth factor receptor (EGFR) are now successfully targeted with agents such as the EGFR tyrosine kinase inhibitor osimertinib. Despite progress, drug resistance remains a barrier to complete and long-term tumor responses. Indeed, most patients do not survive with EGFR mutant lung cancer as a chronic disease and instead succumb to the disease within a few years due to the emergence of resistance.

Editorial on Mechanisms of Resistance to EGFR-targeted Therapy
EGFR targeted therapy resistance: current status, challenges, and future outlook
Trever G. Bivona

Review Article on Mechanisms of Resistance to EGFR-targeted Therapy
Mechanisms of resistance to osimertinib
Chiara Lazzari, Vanesa Gregorc, Niki Karachaliou, Rafael Rosell, Mariacarmela Santarpia

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
Justin A. Chen, Jonathan W. Riess

Applications of cell-free circulating tumor DNA detection in EGFR mutant lung cancer
Ajaz Bulbul, Alessandro Leal, Hatim Husain

Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer
Beatrice Gini, Nicholas Thomas, Collin M. Blakely

Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer
Ana I. Velazquez, Caroline E. McCoach

The series “Mechanisms of Resistance to EGFR-targeted Therapy” was commissioned by the Editorial office, Journal of Thoracic Disease without any sponsorship or funding. Trever G. Bivona served as the unpaid Guest Editor for the series.